Surviving the valley of death

EBR - European Biopharmaceutical Review

Volumn , Issue SPRING, 2013, Pages 50-54

  Zurdo, Jesús ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; CETUXIMAB; DRUG ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; NEW DRUG; RECOMBINANT ERYTHROPOIETIN;

ANAPHYLAXIS; ARTICLE; BIOPROCESS; CHRONIC DRUG ADMINISTRATION; DRUG ACTIVITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG INDUSTRY; DRUG QUALITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PROCESS DEVELOPMENT; PRODUCTIVITY; RISK ASSESSMENT; TOTAL QUALITY MANAGEMENT;

EID: 84875911503     PISSN: 13690663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Herper M, The truly staggering cost of inventing new drugs. Visit: www.forbes. com/sites/matthewherper/2012/02/10/ the-truly-staggering-cost-of- inventingnew- drugs
2. Paul SM, Mytelka DS, Dunwiddie CT et al, How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nat Rev Drug Discov 9: pp203-214, 2010
3. Pammolli F, Magazzini L and Riccaboni M, The productivity crisis in pharmaceutical R&D, Nat Rev Drug Discov 10: pp428-438, 2011
4. Butler D, Translational research: crossing the valley of death, Nature 453: pp840-842, 2008
5. Pritchard JF, Jurima-Romet M, Reimer MLJ, Mortimer E, Rolfe B and Cayen MN, Making better drugs: decision gates in non-clinical drug development, Nature Rev Drug Discov 2: pp542-553, 2003
6. Rees H, Supply chain management in the drug industry: delivering patient value for pharmaceuticals and biologics, John Wiley & Sons, Inc, 2011
7. Zurdo J, Developability assessment as an early de-risking tool for biopharmaceutical development, Pharmaceutical Bioprocessing 1, 2013
8. Venkatesh S and Lipper RA, Role of the development scientist in compound lead selection and optimization, J Pharm Sci 89: pp145-154, 2000
9. Rosenberg AS, Effects of protein aggregates: an immunologic perspective, AAPS J 8: ppE501-507, 2006
10. Seidl A, Hainzl O, Richter M et al, Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity, Pharmaceut Res 29: pp1,454-1,467, 2012
11. Jameel F and Hershenson S, Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals: pp329- 347, John Wiley & Sons, Inc, 2010
12. Zurdo J, Michael R, Stallwood Y, Hedman K and Aastrup T, Improving the developability of biopharmaceuticals, Inno Pharma Technol 37: pp34-40, 2011
13. Mahler HC and Jiskoot W, Analysis of Aggregates and Particles in Protein Pharmaceuticals, John Wiley & Sons, Inc, 2012
14. Buck PM, Kumar S, Wang X, Agrawal NJ, Trout BL and Singh SK, Computational methods to predict therapeutic protein aggregation, Methods Mol Biol 899: pp425-451, 2012
15. Van De Weert M, Horn Møller E, Immunogenicity of Biopharmaceuticals: pp27-56, 2008
16. Chung CH, Mirakhur B, Chan E et al, Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose, N Engl J Med 358: pp1,109-1,117, 2008
17. ICH S6. Visit: www.ich.org
18. Buttel IC, Chamberlain P, Chowers Y et al, Taking immunogenicity assessment of therapeutic proteins to the next level, Biologicals 39: pp100-109, 2011
19. Barbosa MD, Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters, Drug Discov Today 16: pp345-353, 2011
20. Suntharalingam G, Perry MR, Ward S et al, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, N Engl J Med 355: pp1,018- 1,028, 2006
21. Weissmuller S, Semmler LY, Kalinke U, Christians S, Muller-Berghaus J and Waibler Z, ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation, Blood 119: pp6,268- 6,277, 2012
22. Brennan FR, Morton LD, Spindeldreher S et al, Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies, mAbs 2: pp233-255, 2010